The rise of prostate cancer cases across America is cause for concern among healthcare professionals. As our population continues to survive longer, more instances of this form of male cancer are being detected every single day. Early detection can increase chances for cancer survival for an astonishingly high percentage. It is for this and other important reasons that Cancer Treatment Centers of America promotes screens that are specific for prostate cancer detection. These simple screens are helping to save lives of men around the world. Preventative screening is one of the best current tools that cancer care specialists recommend for decreasing prostate cancer fatality cases.
Cancer Treatment Centers of America have once again partnered with other organization groups like recently Labcorp and NFL teams Alumni Organization past and acting members. They were able to draw many men in to receive their free prostate cancer screening special offer. After enough men received the free tests, these healthcare advocates then reduced the cost of an additional large number of prostate cancer screenings. It is a willingness to do anything that needs done that is bringing down the death toll of prostate cancer deaths each year. This sort of screening saves lives, and allows others to lead longer lives in remission from their killer disease.
With so much information on cancer treatments and prevention therapies, it would seem that everyone would be on board for this simple screen. To increase the number of screens per year, Cancer Treatment Centers of America will continue to lend their name, money and staff time to other promotional preventative cancer screens or tests in the upcoming years. Most patients that have received cancer treatment services from any of the awesome five Cancer Treatment Centers of America institutions, will readily agree that the level of care is extraordinary.
Many people are unaware of all of the coordinating effort going on behind the scenes at Cancer Treatment Centers of America. Based in Florida, this health system is always first to step out when a new treatment modality arises. The computer age has given way to more intensive cancer treatment abilities that deliver finely tuned precise treatments. This healthcare provider joined hands with Nanthealth and Allscripts to explain their newest cancer care strategy. An extensive clinical oncology platform is available that utilizes the technology of a computer program within the parameters of existing cancer care treatment plans.
Unlike previous days, today’s cancer care specialists can rapidly find all available cancer care resource materials with a quick Internet and computer program search. The information that this team gets is totally unbiased. There is never a conflict of interest that would make a lean towards one treatment as opposed to another. The statistical information is logically compiled. A doctor can instantly see available routes of care, and every patient can get even more individualized cancer care treatment. CTCA has long embraced new ideas like geno-testing for cancer type specifics. This is just another addition to CTCA’s stellar cancer treatment choices.
Costs of care including medication, chemotherapy and other treatment options are compiled to allow the healthcare team and the patients to discuss appropriate treatment options in a realistic manner. This leading healthcare institution hopes to share their successes with other providers. The goal is to further standardize all areas of cancer care across the country. This new online data service connects healthcare providers from anywhere that has Internet access. This is a terrific use of rapidly changing computer technology to assist in enabling better and more coordinated care for cancer patients everywhere. Cancer Treatment Centers of America continues providing top-notch cancer care.
To Learn More : http://www.myctca.com
Dr. Clay Siegall was interviewed for the online publication Inspirey, a website created to spread the success stories of entrepreneurs around the world. In the interview titled “Dr. Clay Siegall—CEO, Seattle Genetics”, Mike Munter sought to discover the inspiration behind Seattle Genetics, a biotech company.
In the interview, Munter discovered that Dr. Clay Siegall is a firm believer in hard work. Siegall believes that inspired work habits are the key to success and intelligence and network are secondary.
Siegall reveals that the company only became profitable about ten years after the initial public offering. But after hiring a talented sales team and developing a marketing strategy that involves long negotiation as relationship building, they are able to create contracts of 7 or 8 figures. He believes their selling process is rather unique since the marketing strategy is based in building relationships with the clients and negotiating with a great legal team. Because they have unique products, the sales staff is able to represent the company. He believes the sales team may be one of the most important parts in making the company successful. They developed the process after having some financial difficulties in 1999 and 2000. However, Siegall believes they were able to grow from it and become profitable due to their talented sales team.
The company also produces incredibly unique products. They were the first to have an FDA approved ADC. Their drug, ADCETRIS, is an antibody drug conjugate which combines monoclonal antibodies and cell-killing agents to treat cancer. He was inspired to create the company after realizing the lack of choices in cancer treatment, all of which can be very invasive and harmful to the patient. He realized that choosing between the harsh, systemic chemotherapy that can have deadly side effects, or brutal surgeries and amputations did not leave patients with the best options. He created Seattle Genetics to help those patients.
Prior to starting Seattle Genetics, Dr. Siegall worked with the Bristol-Myers Squibb Pharamaceutical Research Institute as a senior researcher. He also worked with the National Caner Institute and the National Institutes of Health. He is not only the CEO and President of Seattle Genetics, but he has also been a key factor in the capital-raising activities for the company. Under his leadership, the company was able to gain $675 million in financing. He is also a thorough researcher with nearly 70 published works and 15 patents. He led Seattle Genetics to create a variety of antibody-based cancer treatments including ADCETRIS, an FDA approved drug available in 65 countries.